Is Compounded Semaglutide Legal? What Patients Need to Know

Compounded semaglutide has become one of the most searched topics in weight management, and with good reason — brand-name semaglutide medications like Wegovy and Ozempic can cost over $1,000 per month without insurance. Compounded versions have offered a more accessible alternative for many patients. But the legal landscape is complex and evolving. Is compounded semaglutide legal? The answer depends on several important factors that every patient should understand.

Important Distinction: Compounded ≠ Brand-Name

Before diving into the legal analysis, it's critical to understand that compounded semaglutide is not the same as FDA-approved brand-name semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded medications are prepared by pharmacies based on individual prescriptions and have not undergone FDA approval — meaning they have not been through the rigorous clinical trial process that brand-name drugs must complete to demonstrate safety, efficacy, and manufacturing consistency.

This distinction matters because while brand-name semaglutide has extensive clinical trial data supporting its safety and effectiveness, compounded versions are prepared based on the known active ingredient but may differ in formulation, concentration, purity, and bioavailability. Patients should understand this difference when making informed decisions about their treatment.

The Legal Framework: 503A and 503B Pharmacies

The legality of compounded semaglutide depends on the type of pharmacy producing it and the regulatory conditions at the time. Two categories of compounding pharmacies are relevant:

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a pharmacy may compound a medication based on an individual patient prescription from a licensed provider. The medication must be compounded by or under the supervision of a licensed pharmacist, and the pharmacy must comply with applicable state pharmacy regulations.

For 503A pharmacies, compounding of a drug that is "essentially a copy" of a commercially available product is generally restricted unless that product is on the FDA Drug Shortage List. This is a key legal consideration for semaglutide compounding.

503B Outsourcing Facilities

Section 503B pharmacies (outsourcing facilities) are registered with the FDA and subject to more rigorous regulatory oversight, including current Good Manufacturing Practice (cGMP) requirements and regular FDA inspections. 503B facilities can compound medications in larger quantities without individual patient prescriptions, but they face the same commercial availability restrictions regarding drugs not on the shortage list.

503B outsourcing facilities generally offer higher quality assurance due to the more stringent manufacturing and testing requirements they must follow.

The FDA Drug Shortage List: The Critical Factor

The legality of compounded semaglutide has been closely tied to the FDA's Drug Shortage List. Here's the timeline that matters:

In 2022–2023, semaglutide was placed on the FDA Drug Shortage List due to overwhelming demand for Wegovy and Ozempic that exceeded Novo Nordisk's manufacturing capacity. During this shortage period, compounding pharmacies had clear legal authority to compound semaglutide under both 503A and 503B frameworks.

In late 2024 and into 2025, the FDA declared the semaglutide shortage resolved, which significantly changed the legal landscape. When a drug is no longer in shortage, the legal basis for compounding "essentially a copy" of the commercially available product becomes much more restricted.

What This Means for Patients

The removal of semaglutide from the shortage list means the legal authority for pharmacies to compound semaglutide has become more limited. Some pharmacies may have transitioned to compounding semaglutide salt forms (such as semaglutide sodium) that they argue are not "essentially a copy" of the brand-name product, but this approach is subject to legal challenge and FDA enforcement discretion.

The legal situation continues to evolve, with ongoing litigation, FDA guidance updates, and legislative proposals potentially affecting the status of compounded semaglutide. Patients should stay informed about current regulations.

Quality and Safety Considerations

Regardless of legal status, patients considering any compounded medication should understand the quality and safety landscape:

• Compounded drugs are not FDA-approved: They have not undergone the FDA's review process for safety, efficacy, and manufacturing quality
• Quality varies between pharmacies: 503B outsourcing facilities under FDA oversight generally offer more quality assurance than 503A pharmacies, though both must meet applicable standards
• Sterility and potency testing: Reputable compounding pharmacies perform sterility testing, endotoxin testing, and potency verification — ask your pharmacy about their testing protocols
• The FDA has issued warnings: The FDA has warned consumers about risks associated with compounded semaglutide, including reports of adverse events. Some of these may be related to substandard compounding practices rather than the compound itself, but the risk underscores the importance of sourcing from reputable, regulated pharmacies

How to Protect Yourself

If you and your licensed provider determine that compounded semaglutide is appropriate and legally available in your situation, consider these protective steps:

• Verify the pharmacy: Confirm the pharmacy is licensed in your state and, if a 503B facility, registered with the FDA. Check the FDA's outsourcing facility database for inspection history.
• Ask about testing: Request certificates of analysis (COA) showing potency, sterility, and purity testing results
• Get a legitimate prescription: Compounded semaglutide requires a prescription from a licensed provider. Any source offering it without a prescription is operating illegally.
• Be wary of gray market sources: Products sold online without prescriptions, from overseas pharmacies, or at unusually low prices may be counterfeit or substandard
• Report adverse reactions: If you experience any adverse effects, report them to your provider and the FDA's MedWatch program

Brand-Name Alternatives and Access Programs

Given the evolving legal landscape around compounded semaglutide, patients may also want to explore brand-name access options. Manufacturer savings programs and coupons may significantly reduce out-of-pocket costs for some patients. Insurance prior authorization, while time-consuming, may result in coverage for FDA-approved products. Alternative GLP-1 medications with different shortage and compounding statuses may be available. Patient assistance programs from Novo Nordisk and other manufacturers exist for qualifying individuals.

The Bottom Line

The legality of compounded semaglutide is not a simple yes-or-no answer — it depends on the current FDA shortage status, the type of compounding pharmacy, the specific formulation, and applicable state regulations. The landscape has shifted significantly with the resolution of the semaglutide shortage, and patients should stay informed about current regulations.

What remains constant is that any semaglutide treatment — whether brand-name or compounded — should be prescribed and monitored by a licensed provider, sourced from a legitimate, licensed pharmacy, and understood by the patient in terms of both benefits and limitations. Your provider can help you navigate the current options and determine what is both legally available and clinically appropriate for your situation.

This content is for informational purposes only and does not constitute medical advice or legal advice. Regulatory status of compounded medications may change. Consult a licensed healthcare provider and verify current regulations before making treatment decisions.